| SON et al.
| INTRODUCTION
Despite the increasing number of therapeutic options, 1 the prognosis of patients with metastatic renal cell carcinoma (RCC) at diagnosis or those with a metastatic recurrence remains dismal. 2 Although several types of vascular endothelial growth factor-and mechanistic target of rapamycin (mTOR)-targeted drugs have been approved as first-line therapies for the treatment of metastatic RCC, 1 more than 40% of patients do not respond to these agents. 3 In particular, mTOR signaling pathway is a pivotal regulator of cellular growth, differentiation, survival, metabolism, and stress response. [4] [5] [6] [7] mTOR complex 1 (mTORC1) phosphorylates ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-BP1 to modulate translation, autophagy, lipid biosynthesis, mitochondrial biogenesis, and ribosome biogenesis. mTORC2 phosphorylates serum/glucocorticoid regulated kinase 1 (SGK1), Akt, Ras-related C3 botulinum toxin substrate 1 (Rac1), and protein kinase Cα (PKCα) to regulate cell survival, glycolytic enzymes, pentose phosphate pathway enzymes, glutaminase, and cytoskeletal organization. [4] [5] [6] [7] Due to feedback between mTORC1 and mTORC2, crosstalk with other pathways leading to the compensatory activation of extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase pathway (MAPK), 8, 9 and a higher risk of side effects, the therapeutic efficacy of FDA-approved mTORC1 inhibitors such as everolimus is limited. 10 Several studies have demonstrated the importance of natural products as sources of new anticancer drugs. [11] [12] [13] For example, 47% of chemotherapeutics are of natural origin or directly derived from nature, and up to 70% are considered structurally related to natural compounds. 11 Therefore, we focused on the discovery of novel components from natural plants, which could potentiate anticancer activities when combined with mTOR inhibitors in patients with metastatic RCC. Previously, we reported the antitumor and anti-metastatic efficacy of artesunate, a semi-synthetic derivative of the sesquiterpene artemisinin, against advanced RCC, 14 consistent with other antitumor activities including anti-angiogenesis, reversal of multidrug resistance, reactive oxygen species-induced DNA damage, immune stimulation, and improved radiosensitivity. [15] [16] [17] [18] Under the hypothesis that Artemisia annua L. could provide novel candidates for anticancer agents other than artemisinin, 19 we tested the inhibitory effects of MC-4 fraction from the aerial parts of Artemisia annua L. on the growth and metastasis of Caki-1 and 786-O human RCC cell-lines, with the aim to identify natural materials that demonstrate effective antitumor activity against metastatic RCC, either alone or in combination with everolimus.
| MATERIALS AND METHODS

| Chemicals and reagents
Cell culture medium, fetal bovine serum (FBS), and supplements were obtained from Gibco Invitrogen Corporation (Carlsbad, CA, USA). The primary antibodies for p-p53, p27, cyclin B1, cyclin D1, Cyclin-dependent kinase 1 (CDK1), CDK4, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax2), total Poly (ADP-ribose) polymerase (PARP), total caspase 3, p62, microtubule-associated protein 1A/1B-light chain 3 (LC3)-I/II, Beclin-1, autophagy-related 5 (ATG5), phosphatidylinositol 3-kinase (PI3K), phosphatase and tensin homolog (PTEN), pAkt S473 , total Akt, pyruvate kinase muscle isozyme M2 (PKM2), p-mTOR, total mTOR, p-P70S6K, total P70S6K, α-tubulin, and β-actin were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-Ki-67 and anti-Hypoxia-inducible factor 1-alpha (HIF-1α) were purchased from Abcam (Cambridge, UK). Anti-Glucose transporter 1 (GLUT1), anti-cytochrome c, and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Everolimus was purchased from Selleckchem (Houston, TX, USA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). Everolimus was dissolved in dimethyl sulfoxide (DMSO) and stored at −20°C until use. These agents were diluted to appropriate concentrations with culture medium containing 1% FBS. The final concentration of DMSO was less than 0.1% (v/v).
| Extraction and fractionation of MC-4 from Artemisia annua L
The aerial parts of Artemisia annua L. were collected at Yeongyang-gun, Gyeongsangbuk-do, Korea in July 2015.
A voucher specimen (SKKU-Ph-15-010) was deposited at the herbarium of the School of Pharmacy, Sungkyunkwan University. The fresh plant was dried at 25°C for 5 days (below 40% humidity Figure 6A,B) . The components corresponding to five major peaks in GC chromatogram for MC-4 were isolated and identified from spectroscopic data. MC-4 fraction was subjected to silica gel column chromatography.
To yield five compounds, the selected fractions were rechromatographed on silica gel, RP-C 18 , Sephadex LH-20, and preparative thin-layer chromatography using different solvent combinations.
| Cell lines and culture conditions
Human RCC (Caki-1 and 786-O) cell lines and HK-2 cells, an immortalized proximal tubule epithelial cell line from normal adult human kidney, were purchased from the American Type Culture Collection. Authentication of these cell lines was conducted by short tandem repeat profiling to exclude cross-contamination between the cell lines. The RCC cells were maintained in Roswell Park 
| Cytotoxicity assays
Cell viability was determined using 3-(4,5-dimethylthiazo l-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/mL, Sigma-Aldrich) assay. 
| Monodansylcadaverine (MDC) incorporation assay
Exponentially growing cells were cultured on coverslip attached to the dish for 48 hours and then incubated with the indicated drug treatment in DMEM containing 1% FBS for 48 hours.
After washing the cells with cold PBS, they were fixed with 3.75% paraformaldehyde in PBS. Then, the autophagic vacuoles were labeled with MDC, an autofluorescent base capable of accumulating in autophagic vacuoles, by incubating the cells with 0.05 mmol/L MDC at RT for 30 minutes. After incubation, the cells were visualized under a fluorescence microscope at 600× magnification (Olympus FV10i, Tokyo, Japan).
| Transmission electron microscopy (TEM)
For sample preparation, the cells and tumor tissues were fixed in 2.5% glutaraldehyde in PBS (pH 7.4). The samples were further fixed with 1% osmium tetroxide for 1 hour, gradually dehydrated with EtOH gradients, and embedded in epoxy resin. For TEM analysis, sections (70 nm) were cut using a Leica Ultra-CUT ultramicrotome (Leica Microsystems GmbH, Wetzlar, Germany) and contrasted with 0.1% lead citrate and 8% uranyl acetate in 50% EtOH. Ultrathin sections were examined using a transmission electron microscope (Tecnai™ G 2 Spirit, FEI Company, Hillsboro, OR, USA) that operated at 120 kV. Images were captured using a Megaview III CCD camera (Soft Imaging System, Lakewood, CO, USA).
| Cell cycle analysis
Caki-1 and 786-O cells were cultured with everolimus, MC-4, or medium alone (control). After 24 hours, both attached and detached cells were harvested, washed in PBS, and fixed in 70% ice-cold EtOH overnight at 4°C. The fixed cells were pelleted, resuspended in 1 mL PBS with RNAse A (500 μg/mL), and incubated for 30 minutes at 37°C. After addition of 5 μL of staining solution (10 mg of PI in 1 mL of PBS), the cells were incubated for 15 minutes in the dark. The cells were analyzed using a flow cytometer (Guava ® EasyCyte flow cytometer). DNA content was determined using Flowing Software, and data on cell cycle distribution were represented as histograms.
| Western blot analysis
Caki-1 and 786-O cells were cultured with 100 μg/mL MC-4, 1 μmol/L everolimus, or 0.1% DMSO in medium (vehicle control). The cells were harvested by trypsinization and washed twice with cold PBS. For isolation of total proteins, the cells were suspended in PRO-PREP protein extraction solution (iNtRON, Seongnam, Korea). Protein concentrations were measured using a protein assay kit (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. The cell extract containing 20 μg of protein was loaded onto 6%-15% gradient polyacrylamide gels. After sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), the gels were transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA, USA). The membrane was blocked with 5% skim milk, and subsequently incubated with various primary antibodies at 4°C overnight. After washing the membrane for 1 hour with TNA buffer, the membrane was incubated with horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit antibodies (1:10 000) for 1 hour at RT. The blots were developed using an enhanced chemiluminescence (ECL) Plus kit (Amersham Biosciences, Buckinghamshire, UK).
| In vivo antitumor activity in subcutaneous xenografts
Four-week-old female BALB/c nude mice weighing approximately 20 g (Japan SLC Inc., Hamamatsu, Shizuoka, Japan) were housed under controlled temperature ( , where a is the length and b is the width of the tumor. Body weight was recorded before drug administration and at the time of experiment termination. On the 30th day, the mice were euthanized by carbon dioxide asphyxiation. everolimus treatment (oral gavage, 10 mg/kg); (c) MC-4 (oral gavage, 200 mg/kg); and (d) combination treatment with everolimus (oral gavage, 10 mg/kg) and MC-4 (oral gavage, 200 mg/ kg). All the treatments were performed 5 days a week for 33 days from the day following the injection day. Body weight was recorded before tail vein injection until termination of the experiment. On the 34th day, all mice were euthanized by carbon dioxide asphyxiation. Their lungs were resected and fixed in 10% neutral buffered formalin for hematoxylin and eosin staining. Pulmonary nodules were counted microscopically.
| Evaluation of anti-metastatic activity using experimental lung metastasis assays in vivo
| Immunohistochemistry (IHC)
After the tumor sections were incubated with 3% hydrogen peroxide (H 2 O 2 ) for 10 minutes, they were blocked with 3% goat serum containing 0.3% Triton™ X-100 and incubated overnight with anti-Ki-67 (1:250) and PKM2 (1:250) monoclonal antibodies. After reaction with a biotinylated goat anti-mouse secondary antibody, the sections were treated with HRP-streptavidin (Santa Cruz Biotechnology, Dallas, TX, USA). The sections were then analyzed using an UltraVision™ detection system with 3,3′ Diaminobenzidine (DAB) Plus substrate (Thermo Fisher Scientific Inc., Waltham, MA, USA). Photomicrographs of the tumor sections were captured at 200× magnification using a Zeiss Axiophot light microscope equipped with a PAX-it camera (PAXcam, Villa Park, IL, USA).
| Quantification of glutamine and lactate levels
Caki-1 and 786-O cells were seeded at a density of 1 × 10 6 cells per 25-cm 2 culture flask (Corning) and allowed to grow overnight. The culture media were then replaced with fresh complete RPMI media plus 6 mmol/L glucose, and the cells were treated with drugs for 24 hours. To measure the lactate and glutamine concentrations in the conditioned media, the media were centrifuged and the supernatants (50 μL) were subjected to high-performance liquid chromatography (HPLC) analyses. Briefly, a Sunchrom C18 column (250 × 4.6 mm, 5 μm particle size, 300 Å; The Great EurAsia Sci-Tech Development Co., Ltd, Beijing, China) was attached to a HEWLETT PACKARD series 1100 HPLC system that was pre-equilibrated in 20 mmol/L triethylamine [pH 6.5 (adjusted with phosphoric acid)] and 0.1% acetonitrile. After loading, the column was washed with starting solvent for 5 minutes and resolved with an acetonitrile gradient at a flow rate of 0.5 mL/min. The peak ultraviolet traces (260 nm) were quantified by plotting against standard curves.
| Statistical analyses
Data are expressed as the means + standard error of mean (SEM) of at least three independent experiments. Depending on the data distribution, statistical evaluation was performed using Student's t tests for paired observations or using one-way analysis of variance. The data distributions were evaluated for normality using the Shapiro-Wilk test. Tumor volumes were analyzed by Kruskal-Wallis test, followed by Dunn's test. P < 0.05 was considered statistically significant. 
| MC-4 combined with everolimus displays synergistic anticancer activities in targeting human RCC cells via induction of cell cycle arrest and activation of autophagic cell death
The lack of complete response to everolimus in patients with relapsed or relapsed/refractory RCC suggests that some metastatic RCC cells are resistant to mTORC1 inhibition. 21, 22 As shown in Figure 3C , combination of MC-4 (100 μg/mL) and everolimus (1 μmol/L) dramatically enhanced cytotoxicity in RCC cells. We therefore investigated whether synergistic cytotoxicity by this combination may be caused, at least in part, by the modulation of MC-4-induced autophagic cell death by everolimus. Treatment with everolimus affected targets downstream of mTORC2, such as increased phosphorylation of Akt and increased PKM2/GLUT1 expression, in Caki-1 and 786-O cells ( Figure 3D ), indicating that mTORC1 inhibition by everolimus resulted in increased Akt activity through a negative feedback loop. The inhibition of this compensatory feedback by MC-4 was also supported by synergistic reductions in HIF1α, PKM2, and GLUT1 levels when everolimus and MC-4 were used in combination ( Figure 3D ). Although mTOR is hyperactive in VHL-deficient 786-O cells compared to Caki-1 cells with wild-type VHL expression, our data indicate that MC-4-induced cytotoxicity occurs in a VHL-independent manner via cell cycle arrest, apoptosis, and autophagic cell death. The anti-proliferative effect of everolimus was due to G1 arrest in Caki-1 cells and due to G2/M arrest in 786-O cells ( Figure 3E ). Although the combination of MC-4 with everolimus markedly increased apoptotic cell death in RCC ( Figure 3F , left panel), we failed to observe significantly increased cell apoptosis by everolimus and/or MC-4 in RCC cells, suggesting that apoptosis may not play a significant role in the cytotoxic effects of the combination. These results were confirmed by the absence of a significant change in Bcl-2/Bax ratio in RCC cells after combination treatment compared with everolimus treatment alone ( Figure 3F, right panel) . The combination of MC-4 and everolimus markedly increased autophagosomal formation in human RCCs in vitro, as assessed by MDC staining, and this effect was attenuated by the autophagy inhibitor, 3-methyladenine (3-MA), 23 indicating crosstalk between autophagy and cell metabolism pathways ( Figure 3G ). Similarly, we observed an increase in cellular lysosomes as well as autophagic vacuoles and empty autophagosomes, presumably with fully digested contents, following exposure to MC-4+ everolimus in a morphological analysis by TEM ( Figure 3H ). In addition to its role in anabolic pathways, glutamine metabolism may also promote lactate accumulation and exacerbate glycolysis. 24, 25 Increased anabolic metabolite (lactate) and glutamine utilization via concomitant MC-4+ everolimus-induced Akt/PKM2 and mTORC1 pathways could have resulted in marked autophagic cell death ( Figure 3I) . Therefore, mechanistically, we hypothesize that the modulation of autophagy and cancer cell metabolism by combination treatment with MC-4 and everolimus, the autophagy inducer, is a powerful approach that could markedly improve therapeutic outcomes in patients with advanced RCC.
| MC-4 combined with everolimus displays potent inhibition of tumor progression in RCC cell xenograft animal models
We evaluated the antitumor activity of the combination of MC-4 and everolimus in RCC xenograft mouse models to investigate the relevance of coordinate autophagy and mTOR inhibition in RCC tumor growth in vivo. Consistent with the in vitro antitumor effects, treatment with both MC-4 (200 mg/kg) and everolimus (10 mg/kg) significantly slowed down tumor growth in subcutaneous xenograft mice models of Caki-1 and 786-O cells compared with the control (Figure 4A,B) . No discernible side effects, such as weight loss ( Figure 4C ) or change in behavior, were observed. Notably, meaningful reduction in lung metastatic foci was observed after combination treatment with MC-4 and everolimus in experimental metastasis models of both RCC cells ( Figure 4D,E) . As shown in Figure 4F , the typical autophagic features of cells were observed after combination treatment with everolimus and MC-4, whereas untreated cells had normal nuclear and cytoplasmic morphology and significantly lower autophagosomal counts.
To investigate whether the suppression of tumor growth by the combination treatment is also associated with decreased proliferation and increased autophagy in vivo as observed in vitro, we immunostained the tumor sections for Ki-67 and PKM2 ( Figure 4G ). Treatment with everolimus and MC-4, either alone or in combination, led to a reduction in cell proliferation as demonstrated by decreased Ki-67 staining.
Tumors from mice treated with everolimus alone showed a marginal reduction in active PKM2, which was further decreased in tumors from mice treated with the combination ( Figure 4G ). Furthermore, we confirmed that the synergistic effect of the cotreatment resulted in increased autophagic cell death.
| DISCUSSION
An important and promising target for metastatic RCC to date is mTOR, [4] [5] [6] [7] 21 which is a pivotal regulator of the metabolic pathway of a cell. mTOR receives input from sensors of energy, nutrients, and stress and produces output that regulates protein synthesis and cell growth. [4] [5] [6] [7] The activation of class I PI3K could lead to activation of Akt-mTOR signaling pathway, which in turn inhibits autophagy. 26 However, everolimus monotherapy shows inadequate therapeutic benefits owing to the compensatory activation of mTORC2/Akt signaling, which serves as a key resistance factor. 22,27-29 Therefore, concurrent treatment of metastatic RCC with mTORC1 inhibitors and other targeted agents has been studied to enhance antitumor effects by parallel inhibition of multiple oncogenic signaling pathways. Owing to these concerns, we chose to combine MC-4 with everolimus to determine whether this combination could potentiate autophagic flux leading to cell death in RCC cells without side effects. The proposed mechanism is summarized in Figure 5 .
Our results indicate that the simultaneous targeting of tumor cell growth and autophagic cell death by MC-4 and everolimus results in synergistic antitumor activity mediated by dual inhibition of Akt/PKM2 and mTOR pathways, providing an unexpected opportunity for the development and implementation of drugs targeting cell metabolism and aberrant Akt/ PKM2 signaling. Consistent with these results, previous preclinical studies demonstrated that knockdown of PKM2 can inhibit gastric cancer cell proliferation and G1-S phase transition, attenuate gastric cancer cell migration, and promote autophagy, which may depend on mediating the PI3K/Akt signaling. 30 These findings suggest that PKM2 might serve as a novel prognostic biomarker and target that would allow for a novel treatment strategy for metastatic RCC in clinical settings. The enhanced antitumor efficacy and autophagic cell death mediated by combination treatment with MC-4, a novel compound extracted from Artemisia annua L., and everolimus via simultaneous inhibition of Akt/PKM2 and mTOR pathways provide a mechanistic rationale to evaluate mTOR inhibitors combined with MC-4 in clinical studies on patients with metastatic RCC. The findings of this study would encourage further clinical studies combining MC-4 with established chemotherapeutics as a strategy to treat patients with rapidly progressing RCC, regardless of VHL gene mutation status. We focused further on the discovery of novel therapeutics from natural compounds for metastatic RCC and found that MC-4 consisted of five major components with different cytotoxic effects in RCC cells. The compounds corresponding to five major peaks in GC chromatogram for MC-4 were identified as artemisia ketone (RT, 14.525 minutes), 6,10,14-trimeth ylpentadecan-2-one (RT, 24.466 minutes), ethyl palmitate (RT, 25.870), ethyl linoleate (RT, 27.498), and ethyl linolenate (RT, 27.569) from spectroscopic data ( Figure 6A,B) . As these pure compounds have not been previously reported to have anticancer activity, we compared the potential anticancer activities of the major components in RCC cells.
As shown in Figure 6C , 6,10,14-trimethylpentadecan-2-one exhibited the strongest antiproliferative activities on Caki-1 and 786-O cells, with an IC 50 value of 15 μg/mL and 20 μg/ mL, artemisia ketone with an IC 50 value of 36 μg/mL and 20 μg/mL, followed by ethyl linolenate (IC 50 = 41 μg/mL and 43 μg/mL), ethyl linoleate (IC 50 = 59 μg/mL), and ethyl palmitate (IC 50 = 85 μg/mL and 54 μg/mL). Thus, we concluded that the two components, artemisia ketone and 6,10,1 4-trimethylpentadecan-2-one, exhibiting greater cytotoxicity both in Caki-1 and 786-O cells should be evaluated for therapeutic potential against RCC. In addition, the most potent cytotoxicity in Caki-1 cells and 786-O cells was induced by combination treatment of artemisia ketone with everolimus ( Figure 6D) . Thus, the combination of artemisia ketone and everolimus may provide us a new approach to reverse drug resistance in patients with RCC. MC-4 or each major component (artemisia ketone and 6,10,14-trimethyl pentadecan-2-one) in combination with everolimus showed synergistic cytotoxic effects in RCC cells. We also confirmed the results based on morphological changes and shrinkage of cells leading to cell death induced by each component or MC-4 in combination with everolimus in RCC cell lines (data not shown). Further investigations into the mechanism of the combination are underway.
Autophagic cell death, an alternative cell death pathway to apoptosis, mediates the antitumor ability of a number of mTOR inhibitors or AMP-activated protein kinase activators. 31, 32 It mitigates cellular oxidative stress, probably by disposing damaged organelles, especially mitochondria. 33 Sustained autophagy may eventually cause cell death when protein and organelle turnover exceeds cell capacity. For example, dual targeting of autophagic regulation with autophagy enhancers produced therapeutic benefits via cytotoxic autophagic flux in glioma. 34 As mTORC1 complex is currently considered the autophagy master switch acting like a sensor of nutrient levels to promote proliferation and inhibit autophagy by signaling to the Unc-51 like autophagy activating kinase 1 (ULK1) complex, 37 mTORC1 inhibitors have been shown to induce autophagy in tumor cells. [38] [39] [40] Pharmacologic blockage of mTORC1 can mimic starvation and promote dissociation of mTORC1 from the complex of ATG13 with ULK1 and ULK2, thereby leaving ULK1-2 free to initiate autophagy. 38 Based on these rationales, several early phase clinical trials are ongoing to evaluate the safety and activity of combined autophagy-mTOR inhibition. 41, 42 In this study, the obvious accumulation of autophagosomes in MC-4-treated cells implies that MC-4-induced autophagic cell death supported by reduced p62 levels is associated with increased functional autophagic flux in both the human RCC cell lines compared with control cells. 43 Notably, autophagy was significantly induced by the combination of everolimus and MC-4, with marked beclin I and LC3-II activation, indicating that everolimus and MC-4 synergistically inhibit mTOR activation, which leads to autophagic and not apoptotic cell death. Increased glutamine metabolism, which is a commonly observed metabolic alteration in cancer cells, promotes lactate accumulation and inhibits glycolysis. 25, 44 However, active mTORC1 and Akt in cancer cells promote the "rewiring" of multiple key nodes of central carbon metabolism to increase glucose flux into glycolysis via the pentose phosphate pathway, thereby ensuring the production of the bioenergetic (ATP) and anabolic requirements of cellular growth and proliferation. 45, 46 In particular, Akt/mTORC1 activation upregulated PKM2, which catalyzes one of the final steps of glycolysis by dephosphorylating phosphoenolpyruvate to pyruvate. 47 Recently, PKM2 has been shown to play an important role in the reprogramming and maintenance of altered metabolism in cancer cells and has also been demonstrated to directly regulate gene expression and subsequent cell cycle progression. 48, 49 Furthermore, inhibition of mTOR pathway reduces glucose uptake by downregulating GLUT1 activity. 46 Therefore, co-targeting mTORC1/Akt and glycolysis via GLUT1/PKM2 prevents metabolic rewiring and may lead to better antitumor activity, and GLUT1 and PKM2 dependency might explain the lack of response to agents targeting 24-h incubation, the cells were treated with 6,10,14-trimethyl pentadecan-2-one, ethyl linoleate, ethyl linolenate, and ethyl palmitate up to 80 μg/ mL for 48 h. Cytotoxicity was determined using MTT assay and the results are expressed as percentages of cytotoxicity relative to the untreated control. Data are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. D, Combination effects of each component and everolimus on cell viability. RCC cell lines were treated with MC-4 in combination with everolimus for 48 h. Cell viability was determined by MTT assay and is expressed relative to the value without treatment. The data are means ± SEM from three independent experiments. **P < 0.01, ***P < 0.001
these processes in some population of cancer patients. 50 We demonstrated that MC-4 induced autophagic cell death rather than apoptosis in RCC cells possibly by inhibiting glucose metabolism via a marked decrease in PKM2 and GLUT1 expression modulated by the Akt/PKM2 pathway. As mTORC1 inhibitors such as everolimus activate Akt, the co-administration of a PKM2 inhibitor, such as MC-4, might help overcome this effect and lead to greater cell killing than that observed with mTORC1 inhibition alone. Overall, the present study shows for the first time that PKM2 inhibitors can potentiate the antitumor effects of mTOR1 inhibitors in RCC. Notably, although mTOR is hyperactive in VHL-deficient 786-O cells compared with that in Caki-1 cells with wild-type VHL expression, both RCC cell types showed similar sensitization to everolimus in the presence of MC-4, indicating VHL-independent phosphoinositide 3-kinase /PKM2/mTOR signaling inhibition. These findings reveal the potential therapeutic benefits of clinical application of MC-4 with a lower dose of mTOR inhibitors for metastatic RCC patients by modulating cancer cell metabolism and autophagy.
